Skip to main content
Glama

Data Lv

by io.github.pipeworx-io

Entity Profile

entity_profile
Read-onlyIdempotent

"Tell me about X" / "research Acme" / "brief me on Tesla" / "what does Apple do" / "company profile for Microsoft" / "give me the rundown on NVDA" / "everything you know about $TICKER" — full cross-source profile of a US public company in ONE parallel call. ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view. Fans out across SEC EDGAR, XBRL, USPTO patents, federal contracts (USAspending), FDA-licensed biologics (Purple Book), H-1B hiring (DOL LCA), news and GLEIF, and returns: cik + company_name (+ resolved_from/resolved_to when value was a name); recent_filings (up to 5 with pipeworx://edgar/company/{cik}/filings/{accession} URIs); fundamentals (LATEST 10-K Revenues + NetIncomeLoss + Cash, sorted period_end DESC); patents (USPTO PatentsView API sunset May 2025 — soft-fails until reactivated); federal_contracts (USAspending awards where the company is the recipient); fda_products (FDA-licensed biologics — vaccines, cell/gene therapies — from the Purple Book; a company with only small-molecule/generic drugs will show none here, that is expected, not a failure); hiring (H-1B sponsorship volume + salary range from DOL LCA filings); recent news mentions via GDELT→GNews fallback; LEI via GLEIF. sources_used / sources_failed say which of these actually returned data for THIS company — an empty section is a real "no data", not a bug. Pass a ticker ("AAPL"), zero-padded CIK ("0000320193"), OR a company name ("Moderna") — names now resolve via SEC EDGAR's company-name match; a private company (no CIK/ticker) returns resolved:false with an explicit notes line, not a bare failure. type accepts "company" or "ticker" interchangeably — both take the same value shapes above.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYes"company" or "ticker" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon.
valueYesTicker (e.g., "AAPL"), zero-padded CIK (e.g., "0000320193"), or company name (e.g., "Moderna") — names resolve via SEC EDGAR company-name match.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed3 schema fields changed
    • changedInput schema / properties / type / description
      Previous value: -"Entity type. Only \"company\" supported today; person/place coming soon."New value: +"\"company\" or \"ticker\" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon."
    • changedInput schema / properties / type / enum
      Previous value: -[
-  "company"
-]New value: +[
+  "company",
+  "ticker"
+]
    • changedInput schema / properties / value / description
      Previous value: -"Ticker (e.g., \"AAPL\") or zero-padded CIK (e.g., \"0000320193\"). Names not supported — use resolve_entity first if you only have a name."New value: +"Ticker (e.g., \"AAPL\"), zero-padded CIK (e.g., \"0000320193\"), or company name (e.g., \"Moderna\") — names resolve via SEC EDGAR company-name match."
  2. First observed

TDQS

A4.8/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already mark it readOnly/idempotent/non-destructive, and the description goes well beyond that: it discloses parallel fan-out across sources, the sources_used/sources_failed semantics, USPTO API sunset soft-fail behavior, expected-empty FDA sections for small-molecule companies, and the resolved:false response for private companies. No contradiction with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long but information-dense and front-loaded with the core behavior and usage directive before enumerating sources and return fields. There is minor redundancy with the schema and some repeated examples, but every section contributes useful operational detail for a complex tool.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given no output schema, the description thoroughly enumerates the returned fields, source coverage, failure semantics, edge cases, and accepted input shapes. An agent has enough context to invoke it correctly and interpret results even for unusual cases like private companies or empty FDA sections.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, so the baseline is 3, but the description adds concrete examples (AAPL, zero-padded CIK, Moderna), clarifies that type and value are interchangeable, and explains name resolution via SEC EDGAR. This goes beyond the schema's bare parameter descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a specific verb and resource: it profiles a US public company across many sources in one parallel call. It differentiates itself from chained single-pack lookups and explicitly frames itself as the preferred holistic option, so an agent can distinguish it from narrower sibling tools.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It gives explicit when-to-use signals with concrete user phrasings like 'Tell me about X' / 'research Acme' and instructs to ALWAYS PREFER it over chaining single-pack lookups when a holistic view is requested. It also covers the private-company edge case and what happens then, which is effectively a when-not caveat.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Data Lv toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A4.3/5.0
Disambiguation5/5

Each tool targets a distinct purpose: data lookup (ask_pipeworx vs deep_research), entity profiles, comparisons, memory, monitoring, and prediction market analysis. Overlaps are minimal and mitigated by explicit usage guidance (e.g., ask_pipeworx vs. ask_pipeworx_grounded vs. deep_research).

Naming Consistency5/5

All tools use descriptive snake_case names following a verb_noun or verb_preposition pattern (e.g., entity_profile, resolve_entity, scan_dependency). The naming is predictable and internally consistent, making it easy for an agent to infer tool purposes.

Tool Count3/5

33 tools is on the high end for typical MCP servers. However, the server covers an exceptionally broad domain (structured data across SEC, FDA, FRED, weather, news, crypto, etc.) and includes meta-tools, monitoring, and memory. The count is justified but may feel excessive for many use cases.

Completeness5/5

The tool surface covers the full lifecycle of data access and analysis: discovery (discover_tools, suggest_questions), retrieval (ask_pipeworx, entity_profile), comparison, claim validation, monitoring, memory, and feedback. There are no obvious gaps for the declared domain, and a feedback tool is provided for missing functionality.

Resources